Celcuity ($CELC) Stock Hub: REVTORPYK Approved, the Launch Ahead and the $575M Convertible

01 Where Celcuity stands after approval

Celcuity crossed the line that separates a clinical-stage company from a commercial one on July 14, 2026, when the FDA approved REVTORPYK (gedatolisib) for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer without a detected PIK3CA mutation, after progression on or after at least one line of endocrine therapy in the metastatic setting. The approval covers REVTORPYK in combination with fulvestrant, with or without palbociclib, and rests on the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial. The FDA accepted the application on January 16, 2026, granted Priority Review and set a PDUFA goal date of July 17, 2026; approval came three days ahead of that date.

Three things happened in the four weeks that followed, and each one changes what the next twelve months look like. The National Comprehensive Cancer Network added the regimen to its guidelines as a preferred Category 1 option in the second line and beyond for this population. The company opened an expanded access program so physicians could obtain gedatolisib for eligible patients before commercial supply exists. And on August 13, 2026 the company reported second quarter results showing $754.0 million in cash, cash equivalents and short-term investments at June 30, 2026, against $387.1 million three months earlier.

That liquidity did not come from operations. In June 2026 Celcuity issued $575.0 million of 0.250% convertible senior notes due 2032, raising $557.2 million net, and used $137.4 million of it to retire the Innovatus and Oxford term loan in full. The balance sheet that results is unusual: total liabilities of $841.0 million against total assets of $828.2 million produce stockholders’ equity of negative $12.8 million at June 30, 2026, on the same day the company held three quarters of a billion dollars in liquid assets.

Management states that current cash, cash equivalents and short-term investments finance operations at least into 2029. Shipments of REVTORPYK are expected to begin late in the third quarter of 2026, and a supplemental New Drug Application covering the PIK3CA-mutant population is planned for submission in the same quarter. Neither has happened yet as of August 14, 2026.

02 The central debate: what the market may be mispricing

The share price tells a story that sits oddly beside the clinical and regulatory record. At $85.77 on August 13, 2026, the stock is down 36.33% over the previous quarter and down 14.01% year to date, while remaining up 65.29% over twelve months. The approval that the company had worked toward since licensing gedatolisib in 2021 arrived, and the shares fell over the period that contains it.

What some investors argue is underestimated

The efficacy separation in VIKTORIA-1 is unusually wide for this setting. A hazard ratio of 0.24 for the triplet against fulvestrant in the wild-type cohort, with median progression-free survival of 9.3 months versus 2.0 months, is the kind of margin that supports a durable guideline position rather than a contested one. The Category 1 preferred NCCN listing arrived within weeks rather than after a reimbursement fight. Roughly 70% of breast cancers are HR+/HER2-, and around 60% of those are PIK3CA wild-type, so the approved population is not a niche carved out of a niche. The company also holds a second dataset, in PIK3CA-mutant disease, where gedatolisib beat an active comparator rather than a control arm on endocrine therapy alone.

What is arguably already in the price

A first commercial launch has no revenue history to anchor it, and Celcuity has never sold a product. Operating expenses reached $66.1 million in the second quarter of 2026, of which $35.0 million was selling, general and administrative, up from $7.6 million a year earlier. The cost base has already been built for a launch whose uptake curve is unknown. Short interest stood at 26.38% of float on August 14, 2026, which describes a market where a meaningful cohort is positioned against the outcome.

What would break the constructive case

Slow uptake through the fourth quarter of 2026 and the first quarter of 2027 would be the clearest falsification, because the label and the guideline position are already in place: if prescriptions do not follow, the obstacle is access, administration burden or physician preference rather than evidence. A delayed sNDA submission, a Complete Response on that application, or safety findings in commercial use that differ from the trial population would each undermine a distinct pillar of the case.

03 What Celcuity is today

Celcuity is a Minneapolis-based biotechnology company whose entire value rests on one molecule used across several settings. Gedatolisib, now marketed as REVTORPYK, is a kinase inhibitor of all four class I PI3K isoforms (alpha, beta, delta and gamma) and of both mTOR complexes, mTORC1 and mTORC2. That breadth is the differentiating claim: approved and investigational competitors in this pathway inhibit PI3K-alpha, AKT, or mTORC1 alone or in pairs, and the company’s position is that comprehensive blockade of the PI3K/AKT/mTOR pathway, which the field abbreviates as the PAM pathway, produces a different efficacy and resistance profile.

The molecule is not native to Celcuity. It was licensed from Pfizer on April 8, 2021 under an agreement granting exclusive global development and commercialisation rights, in exchange for $5.0 million upfront, 349,406 shares of common stock, milestone payments of up to $335.0 million in aggregate, and tiered royalties on net sales in low to mid-teens percentages. Celcuity ran the Phase 3 programme, filed the NDA through the FDA’s Real-Time Oncology Review pathway in November 2025, and obtained approval in July 2026.

The development programme now runs on four tracks. VIKTORIA-1 is complete and has produced both the approval and the data package for the planned sNDA. VIKTORIA-2 is enrolling in the first-line setting, with two independent studies covering endocrine-resistant and endocrine-sensitive patients. CELC-G-201 is a Phase 1b/2 trial of gedatolisib with darolutamide in metastatic castration-resistant prostate cancer. And a subcutaneous formulation is in development, aimed at supporting indications where treatment could run for several years and where weekly intravenous administration becomes a practical constraint.

The company reported no revenue in any period through June 30, 2026. Headcount growth in the first half of 2026 was concentrated in the commercial function, which is visible in the selling, general and administrative line more than in research and development, where employee-related and consulting expense also rose.

04 The REVTORPYK label and what it permits

The approved indication is specific, and its boundaries matter more than the headline. REVTORPYK is indicated in combination with fulvestrant, with or without palbociclib, for adult patients with HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy in the metastatic setting. Two features of that sentence carry commercial weight.

First, the label covers both the triplet and the doublet. A physician may add palbociclib or not, which matters because the triplet carries the neutropenia burden and the doublet does not. That flexibility lets the regimen be adapted to patient fitness without going off-label, and it gives the company two shots at the same patient rather than one.

Second, the population is defined by the absence of a mutation. PIK3CA wild-type disease had no approved PAM-pathway option before this, because alpelisib and capivasertib are directed at biomarker-selected populations. Gedatolisib is the first inhibitor targeting the PAM pathway to show positive Phase 3 results in HR+/HER2- PIK3CA wild-type disease progressing on or after a CDK4/6 inhibitor, which is why the guideline body could place it as a preferred option rather than one alternative among several.

The NCCN recommendation, announced by the company after approval, lists REVTORPYK with fulvestrant, with or without palbociclib, as a preferred Category 1 second-line and subsequent-line therapy for this population. Category 1 in that framework denotes high-level evidence and uniform consensus. For a launch, that classification removes one of the two usual frictions; the other, payer coverage, is established prescription by prescription and will not be visible in the numbers until the fourth quarter of 2026 at the earliest.

Administration is intravenous, once weekly for three weeks of every four-week cycle, which is the practical constraint the subcutaneous programme is designed to relieve.

05 VIKTORIA-1 wild-type: the evidence behind the approval

VIKTORIA-1 enrolled at more than 200 clinical sites across North America, Europe, South America and Asia-Pacific, and was built as two independent studies so that PIK3CA wild-type and mutant populations could be evaluated separately. In the wild-type study, patients were randomised 1:1:1 to gedatolisib with palbociclib and fulvestrant, gedatolisib with fulvestrant, or fulvestrant alone. The database cut-off was May 30, 2025, topline data were announced on July 28, 2025, and fuller results were presented at ESMO on October 18, 2025.

The triplet reduced the risk of progression or death by 76% against fulvestrant, a hazard ratio of 0.24 with a 95% confidence interval of 0.17 to 0.35 and p<0.0001. Median progression-free survival by blinded independent central review was 9.3 months against 2.0 months, an incremental 7.3 months. The doublet reduced that risk by 67%, a hazard ratio of 0.33 with a confidence interval of 0.24 to 0.48, and delivered 7.4 months against 2.0 months, an incremental 5.4 months.

Response data followed the same pattern. The approval press release reports an objective response rate of 32% for the triplet against 1% for fulvestrant, with median duration of response of 17.5 months; the second quarter Form 10-Q states 31% for the same comparison, a one-point difference between two company documents that both describe the wild-type cohort. The doublet produced a 28% response rate in the approval release and 28.3% in the Form 10-Q, with a 12.0-month median duration of response. Median duration of response could not be determined for fulvestrant, because a single objective response occurred in that arm.

Two subgroup readings sit behind any commercial model. Among patients enrolled in the United States and Canada, median progression-free survival was 19.3 months for the triplet (hazard ratio 0.13; 90% CI 0.07-0.29) and 14.9 months for the doublet (hazard ratio 0.35; 90% CI 0.17-0.76). At the San Antonio Breast Cancer Symposium in December 2025, the company reported 16.6 months for the triplet and 7.1 months for the doublet against 1.9 months for fulvestrant among patients in the United States, Canada, Western Europe and Asia-Pacific. Those figures come from subgroups rather than the primary analysis, and subgroup estimates in oncology trials are directional rather than definitive.

06 Safety, dose management and the tolerability argument

The safety profile splits cleanly between the two approved regimens, and that split is the commercial argument for having both on the label.

In the wild-type cohort, Grade 3 treatment-related adverse events for the triplet, doublet and fulvestrant arms included neutropenia in 52.3%, 0% and 0.8% of patients; stomatitis in 19.2%, 12.3% and 0%; rash in 4.6%, 5.4% and 0%; and hyperglycemia in 2.3%, 2.3% and 0%. Grade 4 events were principally neutropenia, at 10.0% for the triplet and 0.8% for the doublet. The neutropenia signal belongs to palbociclib rather than to gedatolisib, which is why it disappears in the doublet arm.

Discontinuation is where the profile reads most favourably. Treatment-related adverse events led to discontinuation of study treatment in 2.3% of triplet patients and 3.1% of doublet patients, against 0% on fulvestrant alone. In the mutant cohort, where the comparator was alpelisib plus fulvestrant, 5.2% of triplet patients and 3.8% of doublet patients discontinued gedatolisib because of an adverse event, against 19.1% who discontinued alpelisib. The company recalculated those rates using the same methodology that produced the discontinuation figure in the REVTORPYK label, which makes the comparison internally consistent rather than assembled from differently defined denominators.

The hyperglycemia comparison carries the clearest mechanistic message. Grade 3 or higher hyperglycemia occurred in 2.6% of gedatolisib triplet patients and 0% of doublet patients in the mutant cohort, against 14.5% for alpelisib plus fulvestrant; Grade 3 or higher rash was 6.5% and 5.8% against 15.1%. Alpha-selective PI3K inhibition drives the metabolic toxicity that has limited that class in practice, and the comparative data suggest gedatolisib does not reproduce it at the same rate despite inhibiting the same isoform among others.

The comparison does not run one way. In the same cohort, Grade 3 or higher neutropenia was 58.8% for the gedatolisib triplet and 0% for the doublet, against 0.7% for alpelisib plus fulvestrant, and stomatitis was 16.3% and 5.8% against 5.3%. The metabolic and dermatologic burden favours gedatolisib; the haematologic and mucosal burden of the triplet does not.

One Grade 5 treatment-related event occurred in the gedatolisib triplet group of the mutant cohort, attributed to palbociclib; none occurred in the doublet group, and two occurred in the alpelisib plus fulvestrant group.

Grade 3 tables understate what a patient experiences, and the approved label carries the all-grade figures. Stomatitis occurred in 72% of patients treated with REVTORPYK plus fulvestrant and palbociclib, including Grade 3 events in 22%, and in 58% of patients on REVTORPYK plus fulvestrant, including Grade 3 events in 12%. The label directs prescribers to start a steroid-containing, alcohol-free mouthwash before treatment begins and to continue it prophylactically, and to withhold, reduce or discontinue based on severity. A mandatory supportive-care step of that kind is a practical factor in how a regimen is adopted, separate from how it performs.

Treatment duration data updated as of August 2, 2026 give an early read on persistence. With median follow-up of roughly 21 months in the wild-type cohort and 17 months in the mutant cohort, patients on the triplet had received a mean of 9.0 and 10.0 cycles respectively, and 12% and 22% were still receiving therapy. For the doublet the figures were 9.7 and 11.3 cycles, with 12% and 19% still on treatment.

07 The launch: what has to be proven, quarter by quarter

Celcuity states that the commercialisation infrastructure needed to support the launch is complete, that launch activities began immediately after approval, and that shipments are expected to begin late in the third quarter of 2026. Until shipments start there is no revenue line to examine, which makes the third quarter report the first document that carries commercial information rather than preparation.

The expanded access programme opened in early August 2026 and distributes gedatolisib to participating physicians on behalf of eligible patients ahead of commercial supply. Such programmes serve patients rather than the income statement, and they generate no revenue, but they do put product into clinical hands and create prescriber familiarity before the first commercial order.

The cost of readiness is already visible. Selling, general and administrative expense rose to $35.0 million in the second quarter of 2026 from $7.6 million in the same quarter of 2025. The $27.4 million increase breaks down into $14.5 million of employee-related expense, of which $3.3 million was stock-based compensation, and $12.9 million of other costs, of which $10.8 million was pre-commercial launch spending on consulting, professional fees and infrastructure and $2.1 million other administrative expense. The company states separately that $23.4 million of the $27.4 million related to commercial headcount additions and other launch-related activities. A company that has spent at this rate before a single unit ships has removed the excuse of not being ready.

Three questions will be answered in sequence. Whether shipments begin in the window the company has guided to, which is testable within weeks. Whether the fourth quarter of 2026 produces a revenue figure that indicates real prescribing rather than stocking, which requires the March 2027 annual report to interpret properly. And whether the doublet or the triplet dominates early use, which will indicate how physicians are weighing the neutropenia burden against the efficacy difference, and which in turn affects the palbociclib-related economics of each prescription.

08 The PIK3CA-mutant cohort and the planned sNDA

The second study within VIKTORIA-1 randomised PIK3CA-mutant patients 3:3:1 to the gedatolisib triplet, alpelisib plus fulvestrant, or the gedatolisib doublet. The database cut-off was March 9, 2026, topline results were announced on May 1, 2026, and detailed results were presented in a late-breaking oral session at the ASCO Annual Meeting on June 2, 2026.

This is the harder comparison, because the control arm is an active PI3K-alpha inhibitor rather than endocrine therapy alone. The triplet halved the risk of progression or death against alpelisib plus fulvestrant, a hazard ratio of 0.50 with a 95% confidence interval of 0.37 to 0.68 and p<0.0001, with median progression-free survival of 11.1 months against 5.6 months. The doublet produced a hazard ratio of 0.51, confidence interval 0.33 to 0.79, descriptive p=0.0013, and median progression-free survival of 11.3 months against the same 5.6-month comparator.

Response rates separated as clearly: 49% for the triplet against 26% for alpelisib plus fulvestrant, with median duration of response of 15.7 months against 7.5 months, and 36% for the doublet with a 24.2-month median duration of response. The company describes this as the first Phase 3 trial to demonstrate superiority of one PAM inhibitor over another.

Overall survival, a key secondary endpoint, was immature at the time of analysis and showed what the company characterises as promising trends for both regimens. Immature survival data support nothing on their own, and a later analysis can move in either direction.

Celcuity intends to submit these data to the FDA as a supplemental New Drug Application in the third quarter of 2026, and to file with regulators outside the United States after that submission. An approval in the mutant population would widen the addressable label from roughly 60% of HR+/HER2- patients to substantially all of them in the second-line setting, and would place gedatolisib in direct competition with alpelisib on the strength of a head-to-head Phase 3 result rather than cross-trial inference. The submission has not occurred as of August 14, 2026.

09 VIKTORIA-2, prostate cancer and the subcutaneous programme

VIKTORIA-2 is the first-line programme, and it was restructured in the second quarter of 2026 in a way that enlarges what gedatolisib could eventually cover. The trial now runs two independent studies with separate statistical analysis plans and separate primary endpoints. Study 1 evaluates gedatolisib with palbociclib and fulvestrant against ribociclib with fulvestrant in roughly 440 treatment-naive patients with endocrine-resistant disease. Study 2, added in the second quarter, evaluates gedatolisib with palbociclib and letrozole against ribociclib with letrozole in roughly 740 treatment-naive patients with endocrine-sensitive disease.

Both studies enrol the full intent-to-treat population regardless of PIK3CA status, with progression-free survival by blinded independent central review as the primary endpoint. Roughly 200 sites participate, many of them carried over from VIKTORIA-1. Topline data for Study 1 are expected by the end of 2028 and for Study 2 in 2030. Those timelines put the first-line opportunity outside any reasonable near-term horizon, and the control arms are ribociclib-based regimens that represent current standard of care rather than a weakened comparator.

In metastatic castration-resistant prostate cancer, the CELC-G-201 Phase 1b/2 trial combines gedatolisib with darolutamide. Dose finding has completed evaluation of a 240 mg dose with no adverse events leading to gedatolisib discontinuation and no dose-limiting toxicity criteria met for dose reduction; a 300 mg dose is under evaluation. Once the Phase 1/1b portion completes, the company expects to select the recommended Phase 2 dose or doses and the control arm options for the randomised portion, and to provide updated data and strategy detail during the fourth quarter of 2026.

The subcutaneous formulation programme aims to demonstrate clinical equivalence to the intravenous form. Its purpose is explicitly forward-looking: if gedatolisib moves into first-line use, treatment durations could extend beyond several years, and weekly intravenous infusion for three weeks of every four over that horizon becomes a burden on patients and infusion capacity alike. No timeline for that programme has been disclosed.

10 The filed financial baseline: second quarter 2026

The 10-Q for the quarter ended June 30, 2026 was filed on August 13, 2026 and is the current financial reference for every figure below.

Cash and cash equivalents stood at $182.0 million and short-term investments at $572.0 million, for total liquidity of $754.0 million, against $387.1 million at March 31, 2026 and $441.5 million at December 31, 2025. Total assets were $828.2 million.

Operating expenses for the quarter were $66.1 million against $44.0 million a year earlier. Research and development fell to $31.1 million from $36.4 million, a 15% decrease the company attributes to a $7.0 million reduction in clinical trial costs as VIKTORIA-1 wound down and a $5.0 million reduction in licence milestone costs, partly offset by $3.8 million more in employee-related and consulting expense and $2.9 million more in manufacturing and other costs. Selling, general and administrative expense rose to $35.0 million from $7.6 million. For the first time, the commercial line exceeds the research line.

Net loss was $78.9 million, or $1.44 per share, against $45.3 million and $1.04 a year earlier. The company also presents a non-GAAP adjusted net loss of $58.7 million, or $1.07 per share, which excludes stock-based compensation, non-cash interest expense, non-cash investment items and the loss on debt extinguishment. Of the $20.2 million gap, $11.5 million is the loss on extinguishing the term loan and $6.9 million is stock-based compensation; only the first is a one-off.

Net cash used in operating activities was $55.4 million in the quarter and $110.5 million in the first half, against $36.2 million in the comparable quarter of 2025. Interest expense was $5.4 million in the quarter, of which $1.5 million was non-cash, and $11.5 million in the half, of which $3.0 million was non-cash. Common shares outstanding were 48,922,556 at June 30, 2026 and 48,931,908 as of August 6, 2026 on the 10-Q cover page. A further 6,147,787 pre-funded warrant shares, exercisable for nominal consideration, are included in the earnings-per-share computation, which is why the weighted average behind the $1.44 loss per share is 54,816,437 rather than the common-share count.

Against roughly $55 million of quarterly operating cash burn before any launch costs settle into a run rate, $754.0 million of liquidity supports the company’s statement that operations are financed at least into 2029. Two known cash items sit outside that burn: the $50.0 million milestone owed to Pfizer on approval, and whatever working capital a commercial launch consumes before receivables convert.

All figures are as reported in the Form 10-Q for the relevant period. FY2025 research and development and selling, general and administrative are as reported in the 2025 Form 10-K: in connection with the FDA approval the company reclassified expense from research and development to selling, general and administrative, $6.3 million in the first half of 2025 alone, so the FY2025 split is not on the same basis as the 2026 quarters.

11 How $754 million of cash coexists with negative equity

Stockholders’ equity was negative $12.8 million at June 30, 2026, against positive $100.6 million at December 31, 2025. A company holding three quarters of a billion dollars in liquid assets and reporting an equity deficit looks contradictory until the liability side is read in full, and the explanation is entirely mechanical.

Total liabilities were $841.0 million, of which convertible notes accounted for $753.2 million in carrying value. Two instruments sit in that line. The 2031 notes, whose issuance completed on August 1, 2025, carry a 2.750% coupon on $201.3 million of principal and convert at $51.30 per share, a rate of 19.4932 shares per $1,000, giving 3,923,002 shares issuable at June 30, 2026 against a maximum of 5,296,053. The 2032 notes, issued on June 8, 2026, carry a 0.250% coupon on $575.0 million of principal, including full exercise of a $75.0 million over-allotment option, and convert at $124.53 per share, a rate of 8.0302 shares per $1,000, giving 4,617,361 shares issuable at June 30, 2026 against a maximum of 6,464,306.

Because the notes are recorded as debt while the cash they raised sits in assets, and because accumulated losses have consumed the equity built up over years of financing, the equity line turns negative without anything having deteriorated operationally. The 2032 notes carried a $557.4 million carrying value and a $655.6 million fair value at June 30, 2026, the difference reflecting the option value the market assigned at that date to a conversion price of $124.53. The 2031 notes ran the other way: $195.8 million of carrying value against a fair value of $422.2 million at the same date. Their $51.30 conversion price sits well below the share price, so the market prices that instrument largely as equity and the 3,923,002 shares issuable are economically live rather than contingent.

The term loan is gone. On June 8, 2026 the company paid $137.4 million to retire all principal, interest, fees and expenses under the amended Innovatus and Oxford loan agreement, wrote off $7.3 million of unamortised discounts and recorded an $11.5 million loss on extinguishment. The statement of cash flows shows $137.0 million under repayment of note payable within $422.9 million of net financing inflows for the half; the $0.4 million difference from the payoff amount is accrued interest, which the cash-flow statement classifies elsewhere. Removing a secured, covenanted term loan and replacing it with unsecured convertible notes at a 0.250% coupon lowers cash interest cost sharply and removes the collateral constraint.

Dilution risk is now embedded in conversion rather than in equity issuance. Conversion of both series at the stated rates would add 8.5 million shares. The maximum figures of 11.8 million shares assume the conversion-rate increases that apply on a make-whole fundamental change, meaning a takeover, a de-listing or the company calling the notes, rather than a simple conversion. Measured against the roughly 55.1 million shares that include the pre-funded warrants, the maximum case is about 21%; against common shares alone it is about 24%. The company retains the right to redeem either series from August 6, 2029 if the stock trades above 130% of the conversion price on the specified schedule.

12 Pfizer economics: what each milestone and sale costs

Gedatolisib is licensed, not owned outright, and the terms determine how much of any commercial success reaches Celcuity’s own income statement.

Under the April 8, 2021 licence agreement, Celcuity paid $5.0 million upfront and issued 349,406 shares to Pfizer, and owes milestone payments of up to $335.0 million in aggregate: up to $155.0 million tied to development events and up to $180.0 million tied to commercial events, each payable within 60 days of achievement. The development schedule includes $5.0 million on NDA filing, recorded as research and development expense in June 2025 and paid in January 2026; $50.0 million on FDA approval of an NDA; and seven further development milestones totalling $100.0 million.

The approval milestone was triggered on July 14, 2026. Because that date falls after the balance sheet date but before the financial statements were issued, the company treated the approval as evidence of a contingent obligation existing at June 30, 2026, recognising a $50.0 million accrued licence milestone as a liability and a $50.0 million intangible asset. That intangible will amortise into cost of sales beginning at commercial launch, so the first revenue quarters will carry an amortisation charge alongside whatever gross margin the product generates.

Royalties are the recurring cost. Celcuity owes Pfizer tiered royalties on REVTORPYK net sales in low to mid-teens percentages, subject to reductions for expiry of valid patent claims, amounts due under third-party licences, and generic competition. Applied to any revenue forecast, a royalty in that band plus the amortisation of a $50.0 million intangible plus the commercial infrastructure already built means the contribution margin per dollar of sales is materially below what a wholly owned asset would produce. Up to $180.0 million of commercial milestones sit ahead as well, triggered by sales thresholds the company has not disclosed individually.

Celcuity may terminate the agreement for convenience on 90 days’ notice; Pfizer may not. Either party may terminate for uncured material breach.

13 Market structure, short interest and trading behaviour

The share register and the trading profile both carry information that a purely fundamental reading would miss.

Institutional ownership stood at 95.13% and insider ownership at 20.21% on August 14, 2026, against 48.77 million shares outstanding and a float of 38.91 million. A float that small relative to a $4.18 billion market capitalisation produces price moves disproportionate to the volume behind them, and average daily volume of roughly 1.54 million shares means a single institutional repositioning can dominate a session.

Short interest was 26.38% of float. That is a substantial position against a company that has just been approved and guided to launch, and it can be read two ways: as a bet that commercial uptake disappoints relative to expectations embedded in a $4.18 billion valuation, or as convertible arbitrage hedging associated with $776.3 million of principal across two convertible series. The two explanations are not mutually exclusive, and the second mechanically increases reported short interest without expressing any view on the company.

Price behaviour since approval has been negative. The stock closed at $85.77 on August 13, 2026, down 0.96% on the day, down 7.56% over the week, down 2.85% over the month, down 36.33% over the quarter and down 14.01% year to date, while holding a 65.29% gain over twelve months. Weekly and monthly volatility both sit above 5%.

Retail sentiment on Stocktwits ran at 88.89% bullish against 11.11% bearish on August 14, 2026, with 2,219 watchers following the stream. The series shows readings at or near 100% bullish through late June and the first half of July, easing after the approval. Those are self-reported tags from retail traders and non-professional investors rather than analyst positions, and they describe how one-sided the conversation has become rather than anything about the company.

The Finviz aggregate sell-side target stood at $162.18 on August 14, 2026. Aggregate targets blend notes published at different times under different assumptions, and several of the underlying notes predate both the approval and the second quarter results.

The Finviz share count and float track the most recent cover page it has ingested, which is the May 7, 2026 figure of 48,766,288. The filed count as of August 6, 2026 is 48,931,908, and a further 6,147,787 pre-funded warrant shares sit outside both numbers.

14 A valuation framework that waits for commercial inputs

Celcuity has no revenue, so no earnings or sales multiple applies. What can be framed is the relationship between the current market capitalisation and the commercial outcome it implies.

At $85.77 on August 13, 2026 the equity is worth roughly $4.18 billion. Enterprise value adds $776.3 million of convertible principal and the $50.0 million milestone accrued to Pfizer, and subtracts $754.0 million of liquidity at June 30, 2026, leaving enterprise value a little above the market capitalisation. Against that, the company owes Pfizer royalties in low to mid-teens percentages of net sales, carries a cost base running at roughly $66 million of quarterly operating expense before launch costs normalise, and holds liquidity the company states funds operations at least into 2029.

The company has published the top of the funnel. It estimates roughly 37,000 patients in the United States receiving second-line treatment for HR+/HER2- advanced breast cancer, and, using wholesale acquisition cost and internal duration-of-treatment assumptions, a second-line addressable market of more than $6.0 billion a year. That is a list-price ceiling rather than a forecast: it says nothing about penetration, persistence or the gap between list and net.

The inputs below that ceiling do not exist yet. Net price per patient after gross-to-net adjustments is unknown. The share of prescriptions taking the triplet versus the doublet is unknown, and it changes both efficacy expectations and the palbociclib component of each regimen. Persistence in commercial use is unknown; trial data show a mean of 9.0 to 11.3 cycles depending on cohort and regimen as of August 2, 2026, but commercial populations are typically less fit than trial populations. Payer coverage breadth is unknown.

Three dated events will supply the first real inputs. The third quarter 2026 report, expected in November, should confirm whether shipments began in the guided window. The fourth quarter and full year 2026 report, expected in March 2027, should carry the first revenue figure covering a full quarter of commercial availability. And an FDA decision on the planned sNDA, on a timeline that depends on a submission that has not yet occurred, would determine whether the addressable population is roughly 60% of second-line HR+/HER2- patients or close to all of them.

Until those exist, any valuation is an assumption about uptake wearing the clothes of an analysis.

15 Competitive and treatment-pathway context

The second-line HR+/HER2- setting is where several mechanisms now converge, and gedatolisib enters it with a specific structural advantage and a specific structural disadvantage.

The advantage is the wild-type population. Alpelisib is approved for PIK3CA-mutant disease and capivasertib for tumours with PI3K, AKT1 or PTEN alterations, so biomarker-negative patients progressing after a CDK4/6 inhibitor have had no pathway-directed option. Roughly 60% of HR+/HER2- patients fall into that group, and REVTORPYK now holds a preferred Category 1 NCCN listing there. The head-to-head result against alpelisib in the mutant cohort adds a second argument, though the label does not yet cover that population.

The disadvantage is administration. REVTORPYK is given intravenously once weekly for three weeks of every four-week cycle, while alpelisib and capivasertib are oral. In a setting where patients may remain on therapy for a year or more, that schedule imposes a burden on patients and on infusion centre capacity that oral competitors do not. The subcutaneous programme exists to address exactly this, without a disclosed timeline.

Beyond the PAM pathway, oral selective estrogen receptor degraders are moving through this same line of therapy, with elacestrant already approved for ESR1-mutant disease and further candidates in late-stage development. Those agents compete for the same treatment slot but through a different mechanism, and combinations rather than head-to-head displacement are the more likely outcome. Antibody-drug conjugates are used across this and later lines and compete for the same patients through a different mechanism, and the filings take no position on relative sequencing.

Two smaller companies working in adjacent HR+/HER2- breast cancer approaches trade at a fraction of Celcuity’s valuation: Arvinas at roughly $589 million and Olema at roughly $920 million on August 14, 2026, against $4.18 billion for Celcuity. The gap reflects that Celcuity holds an approval and they do not, which is the distinction the next four quarters will either justify or compress.

Finviz Elite, August 14, 2026. Arvinas and Olema work on estrogen receptor-directed approaches in the same tumour type and are shown as scale reference, not as substitutes for one another.

16 Catalyst calendar and a falsifiable checklist

Every item below is dated from a company statement or a filing, and each is written so that it can be marked right or wrong rather than argued about.

• First commercial shipments of REVTORPYK, late third quarter 2026. Guided by the company on August 13, 2026. Test: shipments confirmed in the third quarter report. A slip into the fourth quarter would be the first missed operational commitment after approval.
• sNDA submission for the PIK3CA-mutant population, third quarter 2026. Confirmed as planned in the second quarter release. Test: an announcement of submission by September 30, 2026. FDA acceptance and any priority review designation would follow separately.
• Third quarter 2026 results, expected November 2026. First report covering part of the commercial period. Test: whether a revenue line appears at all, and what the operating expense run rate settles at once launch spending stops being one-off.
• Updated VIKTORIA-1 data at fourth quarter medical conferences. The company expects to provide further updates on both cohorts. Test: whether longer follow-up preserves the hazard ratios and whether overall survival data mature in a favourable direction.
• mCRPC strategy update, fourth quarter 2026. Recommended Phase 2 dose and control arm selection for CELC-G-201, following completion of the 300 mg evaluation.
• $50.0 million milestone payment to Pfizer. Triggered July 14, 2026, payable within 60 days of achievement. Test: the cash outflow appears in the third quarter statement of cash flows.
• Fourth quarter and full year 2026 results, expected March 2027. First full quarter of commercial availability. This is the report that makes or breaks the launch thesis.
• Ex-United States regulatory submissions, after the sNDA. No dates given.

Two longer-dated items anchor the far end of the calendar: topline VIKTORIA-2 Study 1 data by the end of 2028 and Study 2 data in 2030.

17 Bottom line: the approval is earned, the launch is unproven

Celcuity has done the hard part in the sense that regulators grade. VIKTORIA-1 produced hazard ratios of 0.24 and 0.33 against fulvestrant in the wild-type cohort, the FDA approved REVTORPYK on July 14, 2026 for a population with no prior pathway-directed option, and the NCCN placed the regimen as a preferred Category 1 choice within weeks. The mutant cohort then beat an active comparator head to head, giving the company a second filing rather than a second trial to run.

What remains unproven is everything commercial. No unit has shipped as of August 14, 2026. The selling, general and administrative line has already scaled to $35.0 million a quarter against a revenue line that does not exist. The $50.0 million milestone to Pfizer is owed, royalties in low to mid-teens percentages will apply to every dollar of sales, and a $50.0 million intangible will begin amortising into cost of sales at launch.

The balance sheet has been rebuilt for that transition rather than for survival. Total liquidity of $754.0 million at June 30, 2026 funds operations at least into 2029 on the company’s own statement, the secured term loan has been retired, and the 2032 tranche carries a 0.250% coupon and a $124.53 conversion price well above the current share price. The older 2031 notes convert at $51.30 and are already in the money. The negative $12.8 million equity figure is an accounting consequence of that structure, not a signal of distress.

The market has priced the gap between the two halves of that description. The stock is down 2.85% over the month that contains the approval and 36.33% over the quarter, most of which precedes it, and short interest sits at 26.38% of float. Together they describe a set of investors waiting for evidence that prescriptions follow guidelines. The third quarter report in November 2026 and the full year report in March 2027 are where that evidence arrives.